Showing 1 - 6 results of 6 for search 'Hideki Goto', query time: 0.18s Refine Results
  1. 1
    Hetero-Type Benzannulation Leading to Substituted Benzothio-Phenes

    Hetero-Type Benzannulation Leading to Substituted Benzothio-Phenes by Taro Kono, Ryosuke Sasaki, Hideki Goto, Masatoshi Kakuno, Yoo Tanabe

    Published 2021-11-01
    Get full text
    Article
  2. 2
    Pseudotumor of the skin due to Mycobacterium genavense

    Pseudotumor of the skin due to Mycobacterium genavense by Suguru Kurosawa, Keisuke Imafuku, Sho Nakakubo, Sumio Iwasaki, Takanori Teshima, Hideki Goto, Hideyuki Ujiie

    Published 2023-09-01
    Get full text
    Article
  3. 3
    P1526: THE RISK OF DEVELOPING PNEUMOCYSTIS JIROVECII PNEUMONIA PERSISTS EVEN AFTER COMPLETION OF IMMUNOSUPPRESSANTS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS

    P1526: THE RISK OF DEVELOPING PNEUMOCYSTIS JIROVECII PNEUMONIA PERSISTS EVEN AFTER COMPLETION OF IMMUNOSUPPRESSANTS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS by Takahide Ara, Shota Yokoyama, Yuta Hasegawa, Hiroyuki Ohigashi, Toshihiro Matsukawa, Atushi Yasumoto, Souichi Shiratori, Hideki Goto, Masahiro Onozawa, Masao Nakagawa, Kaoru Kahata, Tomoyuki Endo, Daigo Hashimoto, Takanori Teshima

    Published 2023-08-01
    Get full text
    Article
  4. 4
    P1414: CRP IS A CONVENIENT PREDICTIVE MARKER OF THE ANTIPYRETIC EFFECT OF TOCILIZUMAB ON CRS DURING CAR-T CELL THERAPY

    P1414: CRP IS A CONVENIENT PREDICTIVE MARKER OF THE ANTIPYRETIC EFFECT OF TOCILIZUMAB ON CRS DURING CAR-T CELL THERAPY by Shota Yokoyama, Takahide Ara, Shinpei Harada, Yuto Mori, Yuta Hasegawa, Hiroyuki Ohigashi, Toshihiro Matsukawa, Atsushi Yasumoto, Souichi Shiratori, Masahiro Onozawa, Masao Nakagawa, Kaoru Kahata, Tomoyuki Endo, Daigo Hashimoto, Hideki Goto, Takanori Teshima

    Published 2023-08-01
    Get full text
    Article
  5. 5
    P1086: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE

    P1086: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS... by Takahiro Kumode, Wataru Munakata, Hideki Goto, Noriko Fukuhara, Tatsu Shimoyama, Masahiro Takeuchi, Toshiro Kawakita, Kohmei Kubo, Masashi Sawa, Toshiki Uchida, Yuko Mishima, Michiko Ichii, Miyoko Hanaya, Asuka Matsumoto, Masaaki Kuriki, Koji Izutsu, Kenichi Ishizawa

    Published 2023-08-01
    Get full text
    Article
  6. 6
    Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group

    Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematol... by Koh Izumiyama, Tasuku Inao, Hideki Goto, Shinpei Harada, Hajime Senjo, Keito Suto, Junichi Hashiguchi, Reiki Ogasawara, Tomoyuki Saga, Tetsuyuki Igarashi, Kentaro Wakasa, Ikumi Kasahara, Yukari Takeda, Keisuke Yamaguchi, Akio Shigematsu, Mutsumi Takahata, Katsuya Fujimoto, Yoshihito Haseyama, Takahiro Nagashima, Hajime Sakai, Yasutaka Kakinoki, Mitsutoshi Kurosawa, Isao Yokota, Takanori Teshima

    Published 2024-06-01
    Get full text
    Article

Search Tools: